US EditionIllimis Secures Funding for GAIA-Based Alzheimer's Therapeutics
Summary by Pharmaceutical-technology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D Funds to accelerate Alzheimer’s and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14, 2025 /PRNewswire/ — The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therape…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
